Johnson & Johnson will probably not match Boston Scientific's $25 billion offer for Guidant. Media reports suggest that the Guidant board is leaning toward accepting the Boston Scientific bid. The move, which took Wall Street by surprise, has dramatically improved Boston Scientific's standing among analysts. The device maker's stock has languished over the past year, despite the success of its Taxus stent.
- see this article [1] from the AP
Links:
[1] http://news.yahoo.com/s/ap/20051206/ap_on_bi_ge/johnson___johnson_guidant_5